IP Library Granted Patent US 7,622,145
Granted Patent B2
US 7,622,145 · App. 11/189,189 · Granted Nov 24, 2009

Method of coating stents

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,622,145
App. No.
11/189,189
Granted
Nov 24, 2009
Kind
B2
Abstract

Processes for coating implantable medical devices that improve the stability of therapeutic agents contained within the coating.

Claims (24)

1. A process for coating implantable medical devices comprising:

(a) applying a primer coating on the implantable medical devices, including the application of a parylene layer and annealing the parylene layer to reduce autoxidation initiators;

(b) preparing a basecoat solution comprising polymers and a therapeutic agent and applying the basecoat solution to the implantable medical devices coated with parylene, the basecoat solution being prepared with and applied utilizing a process to reduce the presence and exposure of the basecoat solution to oxygen, the implantable medical device with basecoat is dried with recirculating air for at least 30 minutes at a relative humidity of about 30 to about 55 percent;

(c) preparing a topcoat solution comprising at least one polymer and applying the topcoat solution to the implantable medical devices coated with the basecoat solution, the topcoat solution being prepared with and applied utilizing a process to reduce the presence and exposure of the topcoat solution to oxygen;

(d) applying toluene that has the potential to redissolve the coating components and alter the surface finish and the dissolution properties of the therapeutic agent, and drying the implantable medical device with topcoat and toluene with recirculating air for at least 30 minutes at a relative humidity of about 30 to about 55 percent;

(e) reducing the solvent content thereby raising the glass transition temperature of the therapeutic agent and creating a coating morphology to protect the therapeutic agent from autoxidation; and

(f) finally processing the implantable medical devices, including inspecting, packaging and sterilizing the coated medical devices, the final processing including protecting the therapeutic agent from autoxidation, reducing the presence of and exposure of all materials to radicals and reducing the presence of and exposure of all materials to oxygen.

2. The process according to claim 1 , further comprising providing higher glass transition temperatures by minimizing exposure to solvents after drying.

3. The process according to claim 1 , further comprising storing the medical devices in a solvent-free environment.

4. The process according to claim 1 , further comprising increasing removal of residual solvents by allowing a predetermined period of time to elapse for removal thereof post-coating.

5. The process according to claim 1 , further comprising applying vacuum and heat to enhance residual solvent removal.

6. The process according to claim 1 , further comprising increasing removal of residual solvents by reducing the water content.

7. The process according to claim 1 , wherein final processing further comprises vacuum packaging under inert gas.

8. The process according to claim 1 , further comprising minimizing the presence or exposure to free radicals and autoxidation initiators by using materials with minimal free radicals.

9. The process according to claim 8 , further comprising using tools comprised of inert materials.

10. The process according to claim 8 , further comprising minimizing the presence or exposure to oxygen by using raw materials without free radicals or radical initiators and solvents with low hydroperoxide content.

11. The process according to claim 10 , further comprising minimizing decanting of coating solutions and solvents.

12. The process according to claim 11 , further comprising blanketing with inert gas to reduce dissolved oxygen.

13. The process according to claim 12 , further comprising decreasing levels of oxygen by processing in a nitrogen rich environment.

14. The process according to claim l 3 , further comprising packaging under inert gas.

15. The process of claim 1 , wherein the basecoat is applied to the medical device at once.

16. The process of claim 1 , wherein the basecoat is applied to the medical device incrementally.

17. The process according to claim 1 , wherein the topcoat is applied to the medical device at once.

18. The process according to claim 1 , wherein the topcoat is applied to the medical device incrementally.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2025
From: CARDINAL HEALTH SWITZERLAND 515 GMBH; CARDINAL HEALTH 529, LLC; CORDIS CORPORATION; FLEXIBLE STENTING SOLUTIONS, INC
To: CORDIS US CORP
Reel/Frame 072987/0675 →
SECURITY INTEREST Recorded Oct 1, 2025
From: CORDIS US CORP.; ACCESS CLOSURE, LLC
To: HPS INVESTMENT PARTNERS, LLC
Reel/Frame 072973/0157 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2017
From: CORDIS CORPORATION
To: CARDINAL HEALTH SWITZERLAND 515 GMBH
Reel/Frame 042126/0259 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2007
From: AKERMAN, EUGENA A.; CLEEREN, DIRK; LLANOS, GERARD; MARYANOFF, CYNTHIA A.; PAPANDREOU, GEORGIOS; RION, WILLIAM; SIX, KAREL; TODD, THOMAS L.
To: CORDIS CORPORATION
Reel/Frame 018756/0466 →